Incyte Stock Forecast for 2023 - 2025 - 2030

Updated on 03/29/2024

Stock Rating
9
Price Target
$77.20
Consensus
Outperform
Upside
26.99%
Analysts
8
Stock Rating
9
Upside
26.99%
Analysts
8
Price Target
$77.20

Incyte Stock Forecast and Price Target

If the average 2024 price target of $77.20 recently set by eight prominent experts for Incyte is met, there would be a potential upside of approximately 26.99% from the last closing price in March, 2024. The high estimate is $92.00, and the low is $58.00. If you are interested in INCY stock, you should also look at its competitors.

$77.20

26.99% Upside

Outperform
Outperform

Incyte Fair Value Forecast for 2023 - 2025 - 2030

Incyte's Price has seen impressive growth In the last four years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $146.11 – an increase of 100.00%. For the next seven years, the forecast is for Fair Value to grow by 100.00%.

2024 Fair Value Forecast
$146.11
2025 Fair Value Forecast
$186.92
2026 Fair Value Forecast
$210.83
2027 Fair Value Forecast
$228.46
2028 Fair Value Forecast
$224.35
2029 Fair Value Forecast
$146.35
2030 Fair Value Forecast
$144.18
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ABBV Stock Forecast AbbVie Outperform 9
$179.63 Buy/Sell $178.42 0.21%
MRK Stock Forecast Merck Outperform 2
$122.77 Buy/Sell $130.51 9.96%
ROG Stock Forecast Roche Holding Hold 16
CHF242.00 Buy/Sell CHF307.83 11.57%
AZN Stock Forecast AstraZeneca PLC Outperform 17
£104.50 Buy/Sell £165.99 53.79%
NOVN Stock Forecast Novartis Outperform 10
CHF88.80 Buy/Sell CHF105.00 23.95%

Incyte Revenue Forecast for 2023 - 2025 - 2030

Incyte's Revenue has seen impressive growth In the last three years, rising from $2.67B to $3.70B – a growth of 38.59%. In the next year, analysts believe that Revenue will reach $4.53B – an increase of 22.63%. For the next seven years, the forecast is for Revenue to grow by 6.72%.

2024 Rev Forecast
$4.53B
2025 Rev Forecast
$5.16B
2026 Rev Forecast
$5.61B
2027 Rev Forecast
$5.78B
2028 Rev Forecast
$5.11B
2029 Rev Forecast
$3.97B
2030 Rev Forecast
$3.94B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
AMGN Stock Forecast Amgen Outperform 4
$275.36 Buy/Sell $303.65 14.40%
SAN Stock Forecast Sanofi Outperform 16
88.32€ Buy/Sell 102.80€ 21.15%
BMY Stock Forecast Bristol-Myers Squibb Hold 2
$54.36 Buy/Sell $58.15 1.18%

Incyte Dividend per Share Forecast for 2023 - 2025 - 2030

2024 DPS Forecast
$0.00
2025 DPS Forecast
$0.00
2026 DPS Forecast
$0.00
2027 DPS Forecast
$0.00
2028 DPS Forecast
$0.00
2029 DPS Forecast
$0.00
2030 DPS Forecast
$0.00
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
REGN Stock Forecast Regeneron Pharmaceuticals Outperform 2
$964.44 Buy/Sell $961.26 8.87%
GSK Stock Forecast GSK Outperform 12
£16.75 Buy/Sell £17.30 11.04%
MRK Stock Forecast Merck KGaA Outperform 18
156.75€ Buy/Sell 190.06€ 9.73%

Incyte Free Cash Flow Forecast for 2023 - 2025 - 2030

2024 FCF Forecast
$1.31B
2025 FCF Forecast
$1.74B
2026 FCF Forecast
$2.13B
2027 FCF Forecast
$2.38B
2028 FCF Forecast
$2.29B
2029 FCF Forecast
$2.19B
2030 FCF Forecast
$2.10B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
4502 Stock Forecast Takeda Pharmaceutical Company Outperform 5
¥4.31k Buy/Sell ¥4.74k 6.63%
4523 Stock Forecast Eisai Outperform 18
¥6.37k Buy/Sell ¥9.58k 31.83%
JAZZ Stock Forecast Jazz Pharmaceuticals Outperform 14
$116.63 Buy/Sell $188.32 59.52%

Incyte EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, Incyte's EBITDA has seen an increase, rising from $-187.53M to $738.52M. This represents a growth of 493.81%. Analysts predict that Incyte's EBITDA will increase in the upcoming year, reaching $1.82B. This would represent an increase of 146.37%. Over the next seven years, experts predict that Incyte's EBITDA will grow at a rate of 241.22%.

2024 EBITDA Forecast
$1.82B
2025 EBITDA Forecast
$2.38B
2026 EBITDA Forecast
$2.82B
2027 EBITDA Forecast
$3.10B
2028 EBITDA Forecast
$2.94B
2029 EBITDA Forecast
$2.70B
2030 EBITDA Forecast
$2.52B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
APLS Stock Forecast Apellis Pharmaceuticals Outperform 6
$60.69 Buy/Sell $71.19 38.41%
IONS Stock Forecast Ionis Pharmaceuticals Outperform 9
$43.26 Buy/Sell $55.60 41.01%
EXEL Stock Forecast Exelixis Outperform 16
$22.46 Buy/Sell $26.44 20.21%

Incyte EBIT Forecast for 2023 - 2025 - 2030

Incyte's EBIT has seen growth In the last three years, going from $-241.24M to $652.36M – a gain of 370.42% In the next year, analysts believe that EBIT will reach $1.45B – an increase of 122.10%. For the next seven years, the forecast is forEBIT to grow by 102.04%.

2024 EBIT Forecast
$1.45B
2025 EBIT Forecast
$2.12B
2026 EBIT Forecast
$2.41B
2027 EBIT Forecast
$2.58B
2028 EBIT Forecast
$1.90B
2029 EBIT Forecast
$1.60B
2030 EBIT Forecast
$1.32B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MOR Stock Forecast MorphoSys Outperform 6
65.52€ Buy/Sell 28.78€ 3.79%
GERN Stock Forecast Geron Buy 6
$2.14 Buy/Sell $4.83 121.96%
PGEN Stock Forecast Precigen Outperform 8
$1.56 Buy/Sell $9.46 348.72%

Incyte EPS Price Prediction Forecast for 2023 - 2025 - 2030

Incyte's EPS has seen impressive growth In the last four years, rising from $-0.42 to $0.00 – a growth of 100.00%. In the next year, analysts believe that EPS will reach $6.05 – an increase of 100.00%. For the next seven years, the forecast is for EPS to grow by 100.00%.

2024 EPS Forecast
$6.05
2025 EPS Forecast
$7.74
2026 EPS Forecast
$8.73
2027 EPS Forecast
$9.46
2028 EPS Forecast
$9.29
2029 EPS Forecast
$6.06
2030 EPS Forecast
$5.97
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
OMER Stock Forecast Omeros Hold 11
$4.20 Buy/Sell $13.00 -100.00%
XFOR Stock Forecast X4 Pharmaceuticals Outperform 4
$0.91 Buy/Sell $3.26 229.67%
KPTI Stock Forecast Karyopharm Therapeutics Outperform 6
$1.48 Buy/Sell $6.00 237.84%